Viruses, Vol. 12, Pages 915: Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccines Despite Similar Levels of Circulating Immunoglobulins

In this study, we compared the long-term functionality of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who received the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) during the Phase I clinical trial in Hamburg. Our study highlights important differences between EBOV vaccination and natural infection and provides a framework for comparison with other vaccine candidates.

Source: Viruses - August 19, 2020 Category: Virology Authors: Till Koch Monika Rottstegge Paula Ruibal Sergio Gomez-Medina Emily V. Nelson Beatriz Escudero-P érez Matthias Pillny My Linh Ly Fara Raymond Koundouno Joseph Akoi Bore N ’Faly Magassouba Christine Dahlke Stephan G ünther Miles W. Carroll Marylyn M. Ad Tags: Article Source Type: research